Centocor Inc. received approval last week for an expanded label for its ReoPro anti-platelet antibody in a wide population of patients undergoing angioplasty, but the company is continuing its pursuit of additional indications. Data presented on Saturday from CNTO's TIMI 14 trial represents an initial step toward clearing ReoPro for medical management of heart attack patients who do not undergo angioplasty.

TIMI 14 is an ongoing open-label dose-finding Phase II trial that is testing the combination of ReoPro with low-dose thrombolytic therapy in patients with acute myocardial infarction. While patients in TIMI 14 were subsequently transferred to the cardiac catheterization laboratory for examination and possible intervention, CNTO's goal is to show that ReoPro can improve outcomes even without